Direct emissions
471,063
tCO2e
Back to search resultsEmissions
Sustainability
Scope
REPORTED ESTIMATED ESTIMATED ESTIMATED ESTIMATED ESTIMATED ESTIMATED ESTIMATED ESTIMATED ESTIMATED ESTIMATED ESTIMATED ESTIMATED ESTIMATED ESTIMATED ESTIMATED 
Read the full scoring methodologyOur white paper covers exactly how the Mycelium Score and Transparency Score are calculated, including the normalisation process and what earns a 10/10.Download the white paper (PDF)
Mycelium Score0.8 / 10Significant room to improveFTransparencyVery LowMinimal disclosure across key areas
Explore carbon emissions data for Teva Pharmaceutical. Mycelium helps you review reported emissions, disclosure status, Scope 1, Scope 2 and Scope 3 data, climate targets and sustainability information in one company profile.
This profile brings together available carbon emissions data for Teva Pharmaceutical, including reported figures, modelled estimates, disclosure documents and sustainability indicators, so you can review its emissions and compare its performance against similar companies. It is one entry in the Mycelium emissions database. Read how we source and check this data.
Emissions
Carbon emissions
Total yearly emissions across all scopes
6,537,418tCO2e
Scope 1
tCO2e
471,063
Scope 2
tCO2e
–
Scope 3 total
tCO2e
6,066,355
Not yet checked against the source report
Scope 3 reported
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
Something wrong? Contribute to this dataset
See the scope breakdownProvenance
Emissions
Factors
0.158kgCO2e / $
Supplier specific emission factors (kgCO2e / $)
Modelled
Reported
UpstreamScope 1, 2 + upstream Scope 3
0.158
0.030
Total+ all Scope 3
–
0.413
Per US dollar of revenue. Mycelium models the upstream factor only.
Which figure should I use?
Estimating your own supply-chain emissions from spend with this company? Use Upstream Modelled. The GHG Protocol defines purchased-goods emissions as cradle-to-gate, which means this company's own operations plus its upstream supply chain. Any of those emissions the company has not disclosed are filled with modelled estimates, so a transparent company is not unfairly penalised against one that simply has not reported.
Looking at what the company filed itself? Use the Reported column. Total Reported also includes downstream emissions, such as the lifetime use of the products this company sells, which the GHG Protocol attributes to the users of those products rather than to customers buying goods and services.
Reported counts only emissions the company has filed itself. A blank or low Reported cell does not mean those emissions do not exist, just that the company has not disclosed them. When Upstream Reported sits close to Upstream Modelled, that is a positive signal: the company has disclosed most of its upstream emissions.
Sustainability
Snapshot
Based on reported data, retrieved with AI
- Teva Pharmaceutical reported 6,537,418 tCO₂e in 2023.
- Scope 3 accounted for 93% of reported emissions.
According to available emissions disclosures, Teva Pharmaceutical reported total yearly emissions of 6,537,418 tCO₂e in 2023. Scope 3 emissions accounted for 93% of the reported footprint, indicating supply chain activity, purchased goods and services, business travel, and wider operational dependencies were the most significant contributors to the company's carbon footprint.
The company achieved a Mycelium Score of 0.8, placing it well below average for its sector for sustainability performance, and received a transparency score of 16.5, pointing to very little public detail on their key emissions.
Scope
breakdown
Scope 1 emissions
Direct emissions from sources the company owns or controls, such as fuel use, facilities and vehicles.
Scope 2 emissions
Indirect emissions from purchased energy, including electricity, heating and cooling.
Purchased energy
–
tCO2eScope 3 emissions
Wider value chain emissions across the 15 GHG Protocol categories, from purchased goods and business travel to investments, where reported.
Teva Pharmaceutical reported a Scope 3 total of 6,066,355 tCO₂e but did not break it down into the 15 categories. That is at least as much as Mycelium's model of the categories it did not report, so the reported figure stands in the total, and the estimates below show where it is likely to sit.
Cat 1
Purchased goods & services
1,401,580
tCO2eCat 2
Capital goods
148,294
tCO2eCat 3
Fuel & energy related activities
114,777
tCO2eCat 4
Upstream transportation & distribution
278,032
tCO2eCat 5
Waste generated in operations
16,888
tCO2eCat 6
Business travel
20,218
tCO2eCat 7
Employee commuting
31,064
tCO2eCat 8
Upstream leased assets
17,542
tCO2eCat 9
Downstream transportation & distribution
122,310
tCO2eCat 10
Processing of sold products
41,996
tCO2eCat 11
Use of sold products
561,641
tCO2eCat 12
End-of-life treatment of sold products
19,640
tCO2eCat 13
Downstream leased assets
12,570
tCO2eCat 14
Franchises
53,626
tCO2eCat 15
Investments
94,607
tCO2e15 values were derived via Mycelium's normalisation process rather than reported by the company. The company's own Scope 3 total is reported, it was simply filed as a single figure with no category split. A cell marked “ESTIMATED” is a figure the company did not disclose, modelled by Mycelium.
Verification
Independent third parties involved in checking or preparing Teva Pharmaceutical's emissions data.
Independent assurance
Independently assured(limited assurance)by DNV Business Assurance Italy S.r.l. (DNV)for 2023
Climate targets
Science Based Targets initiative
Near-term target
Targets set (1.5°C), target year 2030
Source: Science Based Targets initiative, Companies Taking Action.
Contact Info
Website
www.tevapharm.comCountry
Israel
Browse carbon emissions data by industry
Jump straight into the sectors users explore most, or view all industries.
How scoring works
How the Mycelium Score is calculated
The Mycelium Score is out of 10. Up to 6.5 points reflect carbon intensity vs peers in the same NACE section (emissions normalised against revenue, log-scaled between the 5th and 95th percentile of each company's latest reporting year in that section; a section needs at least 5 companies to be benchmarked). The band above 6.5 is earned through verified data quality on a claimed profile: declaring every reporting category yourself (up to 2.0), preparation by a carbon accountant (2.0) and independently audited figures (2.0). The total is multiplied by the transparency score and capped at 10. A disclosure with an implausibly large figure (Scope 1 or 2 over 300 million tonnes, a Scope 3 figure over 2 billion tonnes or a total over 2.5 billion tonnes) is not scored until it has been checked.
A higher score means lower carbon intensity than sector peers, backed by data that's third-party verified, claimed by the company, and fully disclosed. Teva Pharmaceutical's score sits at the top of this page and in the score panel. Without a revenue figure to measure carbon intensity, or an industry classification to compare it within, a company has no score.
How the Transparency Score is calculated
The Transparency Score is the share of a company's estimated footprint that it reported itself, graded from A (very high) down to F (very low). Where a category is missing, Mycelium models what it would hold for a company of that size and industry and counts it as undisclosed, so an unreported category where the bulk of emissions sit hurts far more than a minor one. Unreported downstream categories (9 to 15) count at a quarter of their modelled size in this share; the carbon intensity behind the score still counts them in full. A Scope 3 total filed without a category breakdown earns very little credit for the part left unattributed, because it does not show which categories are inside it: a company can count business travel, leave purchased goods out entirely, and the total looks the same. Without a revenue figure the footprint cannot be modelled, so the company has no Transparency Score.
Teva Pharmaceutical reported a Scope 3 total of 6,066,355 tCO₂e but did not break it down into the 15 categories. It counts towards the footprint, but only a tenth of it counts as disclosed in the transparency score, because it does not show which categories it covers. Breaking it down would be the fastest way to raise the transparency score.
Read the full scoring methodologyOur white paper covers exactly how the Mycelium Score and Transparency Score are calculated, including the normalisation process and what earns a 10/10.Download the white paper (PDF)Compare Teva Pharmaceutical with similar companies
Teva Pharmaceutical carbon emissions FAQs
What are Teva Pharmaceutical's carbon emissions?
In its 2023 reporting year, Teva Pharmaceutical disclosed total emissions of 6,537,418 tCO2e across all scopes. Scope 3 accounted for the largest share of the reported total, around 93%.
Does Teva Pharmaceutical report Scope 1, Scope 2 and Scope 3 emissions?
For 2023, Teva Pharmaceutical's available disclosure covers Scope 1 (471,063 tCO2e) and a Scope 3 total of 6,066,355 tCO2e without a category breakdown. Figures not reported by the company are shown as modelled estimates and labelled as such.
How transparent is Teva Pharmaceutical's emissions reporting?
Teva Pharmaceutical has a Mycelium transparency score of 16.5 out of 100. The score is the share of the company's estimated footprint that it reported itself, so an undisclosed category where most of its emissions sit weighs far more than a minor one.
Is Teva Pharmaceutical sustainable?
Mycelium measures sustainability through carbon emissions data rather than giving a yes or no verdict. Teva Pharmaceutical has a Mycelium Score of 0.8 out of 10, which reflects its emissions intensity against sector peers together with how transparent and well-verified its reporting is. The emissions figures, disclosure documents and climate targets on this page give the fuller picture.
Is Teva Pharmaceutical environmentally friendly?
Carbon emissions are one measurable part of environmental impact, and the part Mycelium tracks. Teva Pharmaceutical disclosed 6,537,418 tCO2e for 2023, and its Mycelium Score of 0.8 out of 10 shows how that performance compares with similar companies in its sector.
Learn more about our methodology and where this data comes from.